ArticleCureus2025
Two Cases of Adult-Onset Esotropia With a History of Medial Rectus Muscle Recession Treated With Botulinum Toxin Type A.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reports on the use of botulinum toxin type A (BTX-A) in patients with esotropia who have previously undergone strabismus surgery are limited. We present two cases of acquired adult-onset esotropia treated with medial rectus recession followed by BTX-A injection and describe the outcomes. In Case 1, a 49-year-old woman underwent bilateral medial rectus recession for acquired concomitant esotropia. Postoperatively, diplopia resolved, but intermittent recurrence was noted 12 months later. At 26 months postoperatively, BTX-A (2.5 units) was injected into the left medial rectus muscle transconjunctivally under electromyography (EMG) guidance. Diplopia resolved shortly after the injection but recurred three months later, prompting a second injection. Follow-up is ongoing. In Case 2, a 62-year-old woman with high myopia and mild abduction limitation underwent bilateral medial rectus recession for esotropia, but ocular alignment did not improve. Five months postoperatively, BTX-A (2.5 units) was injected into both medial rectus muscles transconjunctivally under EMG guidance. Although temporary exotropia developed, ocular alignment gradually improved, and diplopia resolved. As of three months after the injection, there has been no recurrence of esotropia, and the patient remains under observation. In both cases, strabismus surgery and BTX-A injections were performed by the same surgeon. Although the observation period after BTX-A injection was limited to three months in both cases, the treatment was associated with improvement in ocular alignment and resolution of diplopia, while recurrence was noted in one case. BTX-A injection can be performed using standard techniques, even in patients with a history of strabismus surgery, and may provide temporary improvement in ocular alignment. This report provides illustrative evidence of the feasibility of BTX-A treatment, suggesting that it may be considered as one of the potential options for managing recurrent or undercorrected esotropia following medial rectus recession.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.